Alison M Goate, DPhil
- PROFESSOR | Neuroscience
- PROFESSOR | Genetics and Genomic Sciences
- PROFESSOR | Neurology
Dr. Alison Goate is a Professor of Neuroscience, and Director of the Center on Alzheimer's Disease. Her laboratory studies the molecular genetics of dementias and addiction in human populations.
Multi-Disciplinary Training Areas
Genetics and Data Science [GDS], Neuroscience [NEU], Pharmacology and Therapeutics Discovery [PTD]Education
BSc, Hons, University of Bristol
DPhil, Linacre College, University of Oxford
Postdoctoral Research Fellow, Eleanor Roosevelt Institute for Cancer Research
Postdoctoral Research Fellow, Institute of Neurology, University College London
Postdoctoral Research Fellow, St. Mary's Hospital Medical School, Imperial College
-
2012
Elected Fellow, American Association for the Advancement of Science -
2005
Carl & Gerty Cori Faculty Achievement Award -
1994
Senior Investigator Award, Metropolitan Life Foundation -
1994
St. Louis Academy of Science Innovation Award -
1993
Potamkin Prize for Alzheimer's disease research -
1993
Zenith Award, Alzheimer's Association -
1989-
Royal Society University Research Fellow
Research in our laboratory focuses on dementia (Alzheimer's disease & frontotemporal dementia) and addiction (alcohol dependence). In each of these projects our goal is to understand the molecular basis of disease in order to identify novel targets for therapeutic development. We use genetic and genomic approaches to identify susceptibility alleles, this work includes genome wide association studies and whole genome/exome sequencing in families multiply affected by disease and in case control cohorts. We have also pioneered the use of endophenotypes to uncover both risk and protective alleles in both our Alzheimer's disease and our alcoholism studies. We have developed induced pluripotent stem cells from individuals with known genetic causes of disease in order to model the effects of these mutations in disease relevant cell types. Functional studies are being undertaken to understand the role of phospholipase D3 variants in Alzheimer's Disease risk, tau mutations in frontotemporal dementia and alpha 5 nicotinic receptor variants in addiction.
For more information, please visit Dr Goate's lab: Genetics of Neuropsychiatric Disease
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Goate during 2018 and/or 2019. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- Eisai Inc.; GlaxoSmithKline
Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose.
- Illumina, Inc.; National Institute of Neurological Disorders and Stroke (NINDS); VIB, KU Leuven; Weill Cornell Medical College
Other Activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership.
- AbbVie Inc.; Biogen Idec; BrightFocus; Donors Cure; Wellcome Trust
Royalty Payments:
- Athena Diagnostics, Inc.; Taconic Biosciences, Inc.
Scientific Advisory Board:
- Baylor College of Medicine; Columbia University; German Center for Neurodegenerative diseases; Indiana University School of Medicine; Queensland Brain Institute; Washington University, St. Louis; denali therapeutics
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.